GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 508 [WO2023154282A1]
Compound class:
Synthetic organic
Comment: BBO-10203 is an oral PI3Kα:RAS interaction inhibitor. It docks covalently, close to the RAS binding domain of PI3Kα, blocking interactions with all RAS isoforms, but does not disrupt PI3Kα activity or insulin homeostasis [1]. This is a mechanism that has antitumour potential.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| BBO-10203 is being evaluted in clinical trial to determine safety and efficacy in a range of advanced solid tumour types. The first clinical study will evaluate BBO-10203 alone and in combination with the anti-HER2 monoclonal therapy trastuzumab. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06625775 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Phase 1 Interventional | TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics | ||